0

Celiac Diseases Drugs Market by Therapy Type and Geography - Forecast and Analysis 2022-2026

  • Published: Jul 2022
  • Pages: 120
  • SKU: IRTNTR45214
Technavio

Enjoy complimentary customisation on priority with our Enterprise License!

Safe and Secure SSL Encrypted

info
close
  • Single User:

    Quick and easy buy and download option

  • Enterprise:

    Flexible option - Complimentary customization included

2500 USD

The celiac diseases drugs market share is expected to increase by USD 601.57 million from 2021 to 2026, and the market’s growth momentum will accelerate at a CAGR of 16.95%.

This celiac diseases drugs market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers celiac diseases drugs market segmentation by therapy type (first line of treatment and second line of treatment) and geography (North America, Europe, Asia, and the Rest of the World (ROW)). The celiac diseases drugs market report also offers information on several market vendors, including 9 Meters Biopharma Inc., Adaptive Biotechnologies Corp., Almirall SA, Amgen Inc., AMYRA Biotech AG, Avaxia Biologics Inc., BioLineRx Ltd., Bristol Myers Squibb Co., Calypso Biotech, GlaxoSmithKline Plc, Glenmark Pharmaceuticals Ltd, Immunogenics LLC, Johnson and Johnson, Precigen Inc., Sanofi, Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Vactech Oy, Zedira GmbH, and Artielle Immunotherapeutics Inc among others.

What will the Celiac Diseases Drugs Market Size be During the Forecast Period?

Celiac Diseases Drugs Market Size

Download Report Sample to Unlock the Celiac Diseases Drugs Market Size for the Forecast Period and Other Important Statistics

 

Celiac Diseases Drugs Market: Key Drivers, Trends, and Challenges

The higher consumption of gluten-containing food is notably driving the celiac diseases drugs market growth, although factors such as poor diagnosis may impede the market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the celiac disease drugs industry. The holistic analysis of the drivers will help deduce end goals and refine marketing strategies to gain a competitive edge.

Key Celiac Diseases Drugs Market Driver

Higher consumption of gluten-containing food is one of the major drivers impacting the celiac diseases drugs market growth. Celiac disease is characterized by an increase in gluten deposition in the body due to the high consumption of food containing gluten. Pizza, cake, soups, beer, bread, cookies, pasta, and burgers are some of the widely consumed food that contains gluten. The consumption of fast food such as pizza and burgers is increasing across the world. For instance, in the US, about 1 in 8 Americans eat pizza on a typical day. Nearly 15% of Americans eat pizza and one in four boys between 6 and 19 years eat pizza on an average day. The consumption of fast food containing gluten is linked to celiac disease. Similarly, the production and consumption of beer have increased in the last decade. Further, a significant rise in per capita income in developed and developing economies has increased the consumption rate of beer among consumers. The growing demand for craft beer has led to an increase in the number of craft brewers across the world.

Key Celiac Diseases Drugs Market Trend

Inorganic growth strategies are one of the major trends influencing the celiac diseases drugs market growth. The inorganic growth strategies are expected to contribute to the growth of the global celiac disease drugs market. These inorganic growth strategies include global mergers and acquisitions (M&A), partnerships, and regional acquisitions. Due to these inorganic growth strategies, the R&D for new molecules, as well as the clinical pipeline of drugs for celiac diseases, will increase. Large vendors acquire smaller players to increase their market share. These strategies are expected to consolidate the market in the future. The fast-track approval of molecules, which were initially developed by small vendors but now is with bigger players, will fuel the market during the forecast period. 

Key Celiac Diseases Drugs Market Challenge

Poor diagnosis is one of the major challenges impeding the celiac diseases drugs market growth. Celiac disease is a very complex disease associated with a variety of symptoms. Since it is an autoimmune disease, it is more difficult to diagnose at the initial stage of the disease due to an underdeveloped biomarker for celiac disease. This disorder often goes untreated, resulting in fewer diagnoses. For instance, clinical observations over the years suggest that four out of five individuals are either misdiagnosed or undiagnosed. Signs and symptoms can begin from early childhood through adulthood. In adults, the age at diagnosis is usually between 30 and 50 years. The average time between the first symptom and diagnosis is about 11 years due to the wide range of non-specific symptoms and the absence of symptoms in some people. This is one of the biggest challenges for this disease. 

This celiac diseases drugs market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2022-2026.

Parent Market Analysis

Technavio categorizes the global celiac disease drugs market as a part of the global pharmaceuticals market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the celiac disease drugs market during the forecast period.

Who are the Major Celiac Diseases Drugs Market Vendors?

The report analyzes the market’s competitive landscape and offers information on several market vendors, including:

 

  • 9 Meters Biopharma Inc.
  • Adaptive Biotechnologies Corp.
  • Almirall SA
  • Amgen Inc.
  • AMYRA Biotech AG
  • Avaxia Biologics Inc.
  • BioLineRx Ltd.
  • Bristol Myers Squibb Co.
  • Calypso Biotech
  • GlaxoSmithKline Plc
  • Glenmark Pharmaceuticals Ltd
  • Immunogenics LLC
  • Johnson and Johnson
  • Precigen Inc.
  • Sanofi
  • Takeda Pharmaceutical Co. Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Vactech Oy
  • Zedira GmbH
  • Artielle Immunotherapeutics Inc

 

This statistical study of the celiac disease drugs market encompasses successful business strategies deployed by the key vendors. The celiac disease drugs market is fragmented and the vendors are deploying organic and inorganic growth strategies to compete in the market.

To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

The celiac diseases drugs market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.

Celiac Diseases Drugs Market Value Chain Analysis

Our report provides extensive information on the value chain analysis for the celiac disease drugs market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.

Which are the Key Regions for Celiac Diseases Drugs Market?

Celiac Diseases Drugs Market Share by Geography

For more insights on the market share of various regions Request PDF Sample now!

58% of the market’s growth will originate from North America during the forecast period. The US is the key market for celiac disease drugs in North America. Market growth in this region will be faster than the growth of the market in regions.

The rising prevalence of celiac disease, growing awareness of celiac diseases, presence of key vendors, and a strong pipeline of drugs in the region will facilitate the celiac diseases drugs market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.

COVID Impact and Recovery Analysis

Countries across North America were severely affected by the COVID-19 pandemic in 2020, which compelled governments to introduce emergency legislation, including restrictions on several business activities. This led to the shutdown of manufacturing units of several industries. However, as most pharmaceutical companies focused on developing vaccines and manufacturing other drugs to support the medical crisis associated with COVID-19, the production volume of drugs for other therapeutic areas declined to a certain extent during the first few months of 2021. This, in turn, resulted in the slow growth of the celiac disease drug market in North America in 2021.

What are the Revenue-generating Therapy Type Segments in the Celiac Diseases Drugs Market?

Celiac Diseases Drugs Market Share

To gain further insights on the market contribution of various segments Request a PDF Sample

The celiac disease drug market share growth by the first line of treatment segment has been significant. This segment is expected to grow at lucrative rates due to the robust pipeline. There are a few drugs, such as Nexvax2, that got fast-track approvals and are expected to drive the market during the forecast period. The impact of these expected approvals will be high because, currently, there are no approved drugs for the management of celiac diseases. 

This report provides an accurate prediction of the contribution of all the segments to the growth of the celiac diseases drugs market size and actionable market insights on post COVID-19 impact on each segment.

 

Celiac Diseases Drugs Market Scope

Report Coverage

Details

Page number

120

Base year

2021

Forecast period

2022-2026

Growth momentum & CAGR

Accelerate at a CAGR of 16.95%

Market growth 2022-2026

$ 601.57 million

Market structure

Fragmented

YoY growth (%)

16.35

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 58%

Key consumer countries

US, Canada, Germany, UK, and France

Competitive landscape

Leading companies, Competitive strategies, Consumer engagement scope

Key companies profiled

9 Meters Biopharma Inc., Adaptive Biotechnologies Corp., Almirall SA, Amgen Inc., AMYRA Biotech AG, Avaxia Biologics Inc., BioLineRx Ltd., Bristol Myers Squibb Co., Calypso Biotech, GlaxoSmithKline Plc, Glenmark Pharmaceuticals Ltd, Immunogenics LLC, Johnson and Johnson, Precigen Inc., Sanofi, Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Vactech Oy, Zedira GmbH, and Arielle Immunotherapeutics Inc

Market dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period. 

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request PDF sample

What are the Key Data Covered in this Celiac Diseases Drugs Market Report?

  • CAGR of the market during the forecast period 2022-2026
  • Detailed information on factors that will drive celiac diseases drugs market growth during the next five years
  • Precise estimation of the celiac diseases drugs market size and its contribution to the parent market
  • Accurate predictions on upcoming trends and changes in consumer behavior
  • The growth of the celiac diseases drugs industry across North America, Europe, Asia, and the Rest of the World (ROW)
  • A thorough analysis of the market’s competitive landscape and detailed information on vendors
  • Comprehensive details of factors that will challenge the growth of celiac diseases drugs market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch

1 Executive Summary

  • 1.1 Market overview
    • Exhibit 01: Executive Summary – Chart on Market Overview
    • Exhibit 02: Executive Summary – Data Table on Market Overview
    • Exhibit 03: Executive Summary – Chart on Global Market Characteristics
    • Exhibit 04: Executive Summary – Chart on Market by Geography
    • Exhibit 05: Executive Summary – Chart on Market Segmentation by Therapy
    • Exhibit 06: Executive Summary – Chart on Incremental Growth
    • Exhibit 07: Executive Summary – Data Table on Incremental Growth
    • Exhibit 08: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
    • Exhibit 09: Parent market
    • Exhibit 10: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
    • Exhibit 11: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
    • Exhibit 12: Market segments
  • 3.3 Market size 2021
    • 3.4 Market outlook: Forecast for 2021-2026
      • Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million)
      • Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
      • Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
      • Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)

    4 Five Forces Analysis

    • 4.1 Five forces summary
      • Exhibit 17: Five forces analysis - Comparison between 2021 and 2026
    • 4.2 Bargaining power of buyers
      • Exhibit 18: Chart on Bargaining power of buyers – Impact of key factors 2021 and 2026
    • 4.3 Bargaining power of suppliers
      • Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026
    • 4.4 Threat of new entrants
      • Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026
    • 4.5 Threat of substitutes
      • Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026
    • 4.6 Threat of rivalry
      • Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026
    • 4.7 Market condition
      • Exhibit 23: Chart on Market condition - Five forces 2021 and 2026

    5 Market Segmentation by Therapy

    • 5.1 Market segments
      • Exhibit 24: Chart on Therapy - Market share 2021-2026 (%)
      • Exhibit 25: Data Table on Therapy - Market share 2021-2026 (%)
    • 5.2 Comparison by Therapy
      • Exhibit 26: Chart on Comparison by Therapy
      • Exhibit 27: Data Table on Comparison by Therapy
    • 5.3 First line treatment - Market size and forecast 2021-2026
      • Exhibit 28: Chart on First line treatment - Market size and forecast 2021-2026 ($ million)
      • Exhibit 29: Data Table on First line treatment - Market size and forecast 2021-2026 ($ million)
      • Exhibit 30: Chart on First line treatment - Year-over-year growth 2021-2026 (%)
      • Exhibit 31: Data Table on First line treatment - Year-over-year growth 2021-2026 (%)
    • 5.4 Second line treatment - Market size and forecast 2021-2026
      • Exhibit 32: Chart on Second line treatment - Market size and forecast 2021-2026 ($ million)
      • Exhibit 33: Data Table on Second line treatment - Market size and forecast 2021-2026 ($ million)
      • Exhibit 34: Chart on Second line treatment - Year-over-year growth 2021-2026 (%)
      • Exhibit 35: Data Table on Second line treatment - Year-over-year growth 2021-2026 (%)
    • 5.5 Market opportunity by Therapy
      • Exhibit 36: Market opportunity by Therapy ($ million)

    6 Customer Landscape

    • 6.1 Customer landscape overview
      • Exhibit 37: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

    7 Geographic Landscape

    • 7.1 Geographic segmentation
      • Exhibit 38: Chart on Market share by geography 2021-2026 (%)
      • Exhibit 39: Data Table on Market share by geography 2021-2026 (%)
    • 7.2 Geographic comparison
      • Exhibit 40: Chart on Geographic comparison
      • Exhibit 41: Data Table on Geographic comparison
    • 7.3 North America - Market size and forecast 2021-2026
      • Exhibit 42: Chart on North America - Market size and forecast 2021-2026 ($ million)
      • Exhibit 43: Data Table on North America - Market size and forecast 2021-2026 ($ million)
      • Exhibit 44: Chart on North America - Year-over-year growth 2021-2026 (%)
      • Exhibit 45: Data Table on North America - Year-over-year growth 2021-2026 (%)
    • 7.4 Europe - Market size and forecast 2021-2026
      • Exhibit 46: Chart on Europe - Market size and forecast 2021-2026 ($ million)
      • Exhibit 47: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
      • Exhibit 48: Chart on Europe - Year-over-year growth 2021-2026 (%)
      • Exhibit 49: Data Table on Europe - Year-over-year growth 2021-2026 (%)
    • 7.5 Asia - Market size and forecast 2021-2026
      • Exhibit 50: Chart on Asia - Market size and forecast 2021-2026 ($ million)
      • Exhibit 51: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
      • Exhibit 52: Chart on Asia - Year-over-year growth 2021-2026 (%)
      • Exhibit 53: Data Table on Asia - Year-over-year growth 2021-2026 (%)
    • 7.6 Rest of World (ROW) - Market size and forecast 2021-2026
      • Exhibit 54: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
      • Exhibit 55: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
      • Exhibit 56: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
      • Exhibit 57: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
    • 7.7 US - Market size and forecast 2021-2026
      • Exhibit 58: Chart on US - Market size and forecast 2021-2026 ($ million)
      • Exhibit 59: Data Table on US - Market size and forecast 2021-2026 ($ million)
      • Exhibit 60: Chart on US - Year-over-year growth 2021-2026 (%)
      • Exhibit 61: Data Table on US - Year-over-year growth 2021-2026 (%)
    • 7.8 Canada - Market size and forecast 2021-2026
      • Exhibit 62: Chart on Canada - Market size and forecast 2021-2026 ($ million)
      • Exhibit 63: Data Table on Canada - Market size and forecast 2021-2026 ($ million)
      • Exhibit 64: Chart on Canada - Year-over-year growth 2021-2026 (%)
      • Exhibit 65: Data Table on Canada - Year-over-year growth 2021-2026 (%)
    • 7.9 Germany - Market size and forecast 2021-2026
      • Exhibit 66: Chart on Germany - Market size and forecast 2021-2026 ($ million)
      • Exhibit 67: Data Table on Germany - Market size and forecast 2021-2026 ($ million)
      • Exhibit 68: Chart on Germany - Year-over-year growth 2021-2026 (%)
      • Exhibit 69: Data Table on Germany - Year-over-year growth 2021-2026 (%)
    • 7.10 UK - Market size and forecast 2021-2026
      • Exhibit 70: Chart on UK - Market size and forecast 2021-2026 ($ million)
      • Exhibit 71: Data Table on UK - Market size and forecast 2021-2026 ($ million)
      • Exhibit 72: Chart on UK - Year-over-year growth 2021-2026 (%)
      • Exhibit 73: Data Table on UK - Year-over-year growth 2021-2026 (%)
    • 7.11 France - Market size and forecast 2021-2026
      • Exhibit 74: Chart on France - Market size and forecast 2021-2026 ($ million)
      • Exhibit 75: Data Table on France - Market size and forecast 2021-2026 ($ million)
      • Exhibit 76: Chart on France - Year-over-year growth 2021-2026 (%)
      • Exhibit 77: Data Table on France - Year-over-year growth 2021-2026 (%)
    • 7.12 Market opportunity by geography
      • Exhibit 78: Market opportunity by geography ($ million)

    8 Drivers, Challenges, and Trends

    • 8.1 Market drivers
      • 8.2 Market challenges
        • 8.3 Impact of drivers and challenges
          • Exhibit 79: Impact of drivers and challenges in 2021 and 2026
        • 8.4 Market trends

          9 Vendor Landscape

          • 9.1 Overview
            • 9.2 Vendor landscape
              • Exhibit 80: Overview on Criticality of inputs and Factors of differentiation
            • 9.3 Landscape disruption
              • Exhibit 81: Overview on factors of disruption
            • 9.4 Industry risks
              • Exhibit 82: Impact of key risks on business

            10 Vendor Analysis

            • 10.1 Vendors covered
              • Exhibit 83: Vendors covered
            • 10.2 Market positioning of vendors
              • Exhibit 84: Matrix on vendor position and classification
            • 10.3 Amgen Inc.
              • Exhibit 85: Amgen Inc. - Overview
              • Exhibit 86: Amgen Inc. - Product / Service
              • Exhibit 87: Amgen Inc. - Key offerings
            • 10.4 AMYRA Biotech AG
              • Exhibit 88: AMYRA Biotech AG - Overview
              • Exhibit 89: AMYRA Biotech AG - Product / Service
              • Exhibit 90: AMYRA Biotech AG - Key offerings
            • 10.5 BioLineRx Ltd.
              • Exhibit 91: BioLineRx Ltd. - Overview
              • Exhibit 92: BioLineRx Ltd. - Product / Service
              • Exhibit 93: BioLineRx Ltd. - Key offerings
            • 10.6 Bristol Myers Squibb Co.
              • Exhibit 94: Bristol Myers Squibb Co. - Overview
              • Exhibit 95: Bristol Myers Squibb Co. - Product / Service
              • Exhibit 96: Bristol Myers Squibb Co. - Key offerings
            • 10.7 Calypso Biotech
              • Exhibit 97: Calypso Biotech - Overview
              • Exhibit 98: Calypso Biotech - Product / Service
              • Exhibit 99: Calypso Biotech - Key offerings
            • 10.8 GlaxoSmithKline Plc
              • Exhibit 100: GlaxoSmithKline Plc - Overview
              • Exhibit 101: GlaxoSmithKline Plc - Business segments
              • Exhibit 102: GlaxoSmithKline Plc - Key news
              • Exhibit 103: GlaxoSmithKline Plc - Key offerings
              • Exhibit 104: GlaxoSmithKline Plc - Segment focus
            • 10.9 Immunogenics LLC
              • Exhibit 105: Immunogenics LLC - Overview
              • Exhibit 106: Immunogenics LLC - Product / Service
              • Exhibit 107: Immunogenics LLC - Key offerings
            • 10.10 Johnson and Johnson
              • Exhibit 108: Johnson and Johnson - Overview
              • Exhibit 109: Johnson and Johnson - Business segments
              • Exhibit 110: Johnson and Johnson - Key news
              • Exhibit 111: Johnson and Johnson - Key offerings
              • Exhibit 112: Johnson and Johnson - Segment focus
            • 10.11 Sanofi
              • Exhibit 113: Sanofi - Overview
              • Exhibit 114: Sanofi - Business segments
              • Exhibit 115: Sanofi - Key news
              • Exhibit 116: Sanofi - Key offerings
              • Exhibit 117: Sanofi - Segment focus
            • 10.12 Takeda Pharmaceutical Co. Ltd.
              • Exhibit 118: Takeda Pharmaceutical Co. Ltd. - Overview
              • Exhibit 119: Takeda Pharmaceutical Co. Ltd. - Product / Service
              • Exhibit 120: Takeda Pharmaceutical Co. Ltd. - Key news
              • Exhibit 121: Takeda Pharmaceutical Co. Ltd. - Key offerings

            11 Appendix

            • 11.1 Scope of the report
              • 11.2 Inclusions and exclusions checklist
                • Exhibit 122: Inclusions checklist
                • Exhibit 123: Exclusions checklist
              • 11.3 Currency conversion rates for US$
                • Exhibit 124: Currency conversion rates for US$
              • 11.4 Research methodology
                • Exhibit 125: Research methodology
                • Exhibit 126: Validation techniques employed for market sizing
                • Exhibit 127: Information sources
              • 11.5 List of abbreviations
                • Exhibit 128: List of abbreviations
              • health: Includes veterinary drugs (excluded from the scope of the report)

                Research Framework

                Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

                TechnavioINFORMATION SOURCES

                Primary sources

                • Manufacturers and suppliers
                • Channel partners
                • Industry experts
                • Strategic decision makers

                Secondary sources

                • Industry journals and periodicals
                • Government data
                • Financial reports of key industry players
                • Historical data
                • Press releases
                Technavio

                TechnavioDATA ANALYSIS

                Data Synthesis

                • Collation of data
                • Estimation of key figures
                • Analysis of derived insights

                Data Validation

                • Triangulation with data models
                • Reference against proprietary databases
                • Corroboration with industry experts
                Technavio

                TechnavioREPORT WRITING

                Qualitative

                • Market drivers
                • Market challenges
                • Market trends
                • Five forces analysis

                Quantitative

                • Market size and forecast
                • Market segmentation
                • Geographical insights
                • Competitive landscape
                Interested in this report?
                Get your sample now!
                Celiac Diseases Drugs market growth will increase by $601.57 million during 2022-2026.
                The celiac diseases drugs market is expected to grow at a CAGR of 16.95% during 2022-2026.
                Technavio has segmented the celiac diseases drugs market by therapy (First line of treatment and Second line of treatment) and geographic (North America, Europe, Asia, Rest of World (ROW), North America, Europe, Asia, and ROW).
                9 Meters Biopharma Inc., Adaptive Biotechnologies Corp., Almirall SA, Amgen Inc., AMYRA Biotech AG, Avaxia Biologics Inc., BioLineRx Ltd., Bristol Myers Squibb Co., Calypso Biotech, GlaxoSmithKline Plc, Glenmark Pharmaceuticals Ltd, Immunogenics LLC, Johnson and Johnson, Precigen Inc., Sanofi, Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Vactech Oy, Zedira GmbH, Artielle Immunotherapeutics Inc are a few of the key vendors in the celiac diseases drugs market.
                North America will register the highest growth rate of 57.96% among the other regions. Therefore, the celiac diseases drugs market in North America is expected to garner significant business opportunities for the vendors during the forecast period.
                The key factors driving the celiac diseases drugs market growth are:
                • Higher consumption of gluten-containing food
                • Inorganic growth strategies
                The celiac diseases drugs market vendors should focus on grabbing business opportunities from the first line of treatment segment as it accounted for the largest market share in the base year.
                • What are the key global market and the regional market share?
                • What are the revenue-generating key market segments?
                • What are the key factors driving and challenging this market’s growth?
                • Who are the key market vendors and their growth strategies?
                • What are the latest trends influencing the growth of this market?
                • What are the variables influencing the market growth in the primary regions?
                • What are the factors influencing the growth of the parent market?
                • Off-the-shelf research reports
                • Reports can be tailored to meet the customer's needs
                • Trusted by more than 100 fortune 500 organizations
                • Information about the market's key drivers, trends, and challenges
                • Parent market analysis
                • Every week, 50,000 people visit our subscription platform
                • Detailed vendors report with competitive landscape
                • Covid-19 impact and recovery analysis
                • Data on revenue-generating market segments
                • Details on the market shares of various regions
                • Five-force market analysis

                Certified ISO 9001 : 2015

                We are ISO 9001:2015 recognized that ensures quality services and product delivery to our clients.

                We are GDPR and CCPA compliant! Your transaction & personal information is protected from unauthorized use.

                Safe and Secure SSL Encrypted
                Technavio

                info
                close
                • Single User:

                  Quick and easy buy and download option

                • Enterprise:

                  Flexible option - Complimentary customization included

                2500 USD

                Technavio Get the report (PDF) sent to your email within minutes.

                Subscribe & Save

                Get lifetime access to our
                Technavio Insights

                Customized Report as per your Business Needs

                • Our analysts will work directly with you and understand your needs
                • Get data on specified regions or segments, competitor and Vendors
                • Data will be formatted and presented as per your requirements
                • We offer $1000 worth of FREE customization at the time of purchase

                Let us help you make report more suited to your requirements.

                • Get a competitive breakdown as per your niche industry
                • Customize the data with various metrics that meet your business prerequisite
                • Understand Revenue Sources, Customers and many more
                • Details on Market Share
                • These customizations are done in a short amount of time by our analysts and industry experts
                Technavio
                Enquire Before Buying
                17,000 reports available | Plans starting from just 5,000 USD | Get FREE trial>>